MedTrace Logo

Study of QMF149 (150/80 µg) Compared With MF Twisthaler® (200 µg) in Patients With Asthma

NCT02892344 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 802

Last updated 2026-01-13

Study results available
· View outcomes & findings →

Summary

The purpose of the trial was to evaluate efficacy and safety of QMF149 150/80 microgram o.d.

delivered via Concept1 compared to MF 200 microgram o.d., delivered via Twisthaler® in terms of lung function and symptom control in poorly (ie inadequately) controlled asthma patients. This study was to assess contribution of LABA as an add-on therapy to low dose ICS monotherapy.

Conditions

  • Mild Asthma

Interventions

DRUG

QMF149 150/80 μg

QMF149 150/80 μg o.d via Concept1

DRUG

MF 200 μg

MF 200 μg o.d. via Twisthaler®

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-16
Primary Completion
2018-11-05
Completion
2018-11-30

Countries

  • Bulgaria
  • Chile
  • Colombia
  • Estonia
  • Germany
  • Hungary
  • India
  • Italy
  • Japan
  • Latvia
  • Lithuania
  • Malaysia
  • Peru
  • Philippines
  • Poland
  • Russia
  • Slovakia
  • South Africa
  • South Korea
  • Sweden
  • Thailand
  • Vietnam

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02892344 on ClinicalTrials.gov